Going beyond systemic fluoropyrimidines with radiation therapy for rectal cancer: what should be the priority?
Publication
, Journal Article
Duda, DG; Willett, CG
Published in: Oncology (Williston Park, N.Y.)
August 1, 2012
Duke Scholars
Published In
Oncology (Williston Park, N.Y.)
ISSN
0890-9091
Publication Date
August 1, 2012
Volume
26
Issue
8
Start / End Page
741 / 743
Citation
APA
Chicago
ICMJE
MLA
NLM
Duda, D. G., & Willett, C. G. (2012). Going beyond systemic fluoropyrimidines with radiation therapy for rectal cancer: what should be the priority? Oncology (Williston Park, N.Y.), 26(8), 741–743.
Duda, D. G., and C. G. Willett. “Going beyond systemic fluoropyrimidines with radiation therapy for rectal cancer: what should be the priority?” Oncology (Williston Park, N.Y.) 26, no. 8 (August 1, 2012): 741–43.
Duda DG, Willett CG. Going beyond systemic fluoropyrimidines with radiation therapy for rectal cancer: what should be the priority? Oncology (Williston Park, NY). 2012 Aug 1;26(8):741–3.
Duda, D. G., and C. G. Willett. “Going beyond systemic fluoropyrimidines with radiation therapy for rectal cancer: what should be the priority?” Oncology (Williston Park, N.Y.), vol. 26, no. 8, Aug. 2012, pp. 741–43.
Duda DG, Willett CG. Going beyond systemic fluoropyrimidines with radiation therapy for rectal cancer: what should be the priority? Oncology (Williston Park, NY). 2012 Aug 1;26(8):741–743.
Published In
Oncology (Williston Park, N.Y.)
ISSN
0890-9091
Publication Date
August 1, 2012
Volume
26
Issue
8
Start / End Page
741 / 743